Cancer systems biology: Harnessing off-target effects

Gaye Saginc; Franziska Voellmy; Rune Linding

doi:10.1038/nchembio.2519

Cancer systems biology: Harnessing off-target effects

Gaye Saginc, Franziska Voellmy, Rune Linding^*

^*Corresponding author for this work

5 Citations (Scopus)

Abstract

The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action

Original language	English
Journal	Nature Chemical Biology
Volume	13
Issue number	12
Pages (from-to)	1204-1205
Number of pages	2
ISSN	1552-4450
DOIs	https://doi.org/10.1038/nchembio.2519
Publication status	Published - 21 Nov 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nchembio.2519

Cite this

@article{01167e764bfc4fe0b015995f80f6c3ab,

title = "Cancer systems biology: Harnessing off-target effects",

abstract = "The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action",

author = "Gaye Saginc and Franziska Voellmy and Rune Linding",

year = "2017",

month = nov,

day = "21",

doi = "10.1038/nchembio.2519",

language = "English",

volume = "13",

pages = "1204--1205",

journal = "Nature Chemical Biology",

issn = "1552-4450",

publisher = "nature publishing group",

number = "12",

}

TY - JOUR

T1 - Cancer systems biology

T2 - Harnessing off-target effects

AU - Saginc, Gaye

AU - Voellmy, Franziska

AU - Linding, Rune

PY - 2017/11/21

Y1 - 2017/11/21

N2 - The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action

AB - The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action

U2 - 10.1038/nchembio.2519

DO - 10.1038/nchembio.2519

M3 - Letter

C2 - 29161245

AN - SCOPUS:85034819030

SN - 1552-4450

VL - 13

SP - 1204

EP - 1205

JO - Nature Chemical Biology

JF - Nature Chemical Biology

IS - 12

ER -

Cancer systems biology: Harnessing off-target effects

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this